Buried deep within his New Yorker article on "New Blood" looking at what are popularly known as cell therapies, Siddhartha Mukherjee finally notes that these cell therapies are genuinely expensive to produce."The estimated cost to manufacture a typical CAR-T infusion is close to six figures."
This was Siddhartha Mukherjee's moment to discuss how the roll out of expensive but effective new drugs or therapies in the United States plays a significant role in our health care costs.
Did he turn and confront the ways that Medicare, Medicaid, and commercial insurance mount modest efforts (and, often, inconsistent efforts) to try to determine when a new product or treatment should be covered by insurance? No, he did not.
Next article, Mr. Mukherjee?